Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase

Alan F. List, Kenneth J. Kopecky, Cheryl L. Willman, David R. Head, Marilyn L. Slovak, Dan Douer, Shaker R. Dakhil, Frederick R. Appelbaum

Research output: Contribution to journalArticlepeer-review


Chronic myeloid leukemia blast phase (CML-BP) cells commonly express the multidrug transporter, P-glycoprotein (Pgp). To determine whether Pgp inhibition improves treatment outcome in CML-BP, the Southwest Oncology Group performed a randomized, controlled trial testing the benefit of the Pgp modulator, cyclosporin A (CsA). Seventy-three eligible patients were assigned to treatment with cytarabine and infusional daunorubicin with or without intravenous CsA. Treatment with CsA yielded no improvement in treatment outcome as measured by the frequency of induction resistance (68% vs 53%), rate of complete remission or restored chronic phase (CR/CP, 8% vs 30%), and survival (3 vs 5 months). Blast expression of Pgp (63%) and LRP (71%) was common, whereas only Pgp adversely impacted the rate of CR/CP (P= .025). We conclude that Pgp has prognostic relevance in CML-BP but that the modulation of Pgp function with CsA as applied in this trial is ineffective.

Original languageEnglish (US)
Pages (from-to)1910-1912
Number of pages3
Issue number5
StatePublished - Sep 1 2002

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase'. Together they form a unique fingerprint.

Cite this